May 1, 2001Expert Opinion on Investigational Drugs
An update on nesiritide for treatment of decompensated heart failure
Why the study?
Does nesiritide improve haemodynamic effects and symptoms compared to intravenous nitroglycerine in patients with acutely decompensated heart failure?
Population
Patients with acutely decompensated heart failure
Comparison
Nesiritide vs Intravenous nitroglycerine
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support nesiritide over nitroglycerin in acute HF; leaves open confirmation in randomized trials.
Structured PICO
Does nesiritide improve haemodynamic effects and symptoms compared to intravenous nitroglycerine in patients with acutely decompensated heart failure?
P
Population
Patients with acutely decompensated heart failure
I
Intervention
Nesiritide (0.2 microgram/kg bolus followed by 0.01 microg/kg/min continuous infusion)
C
Comparator
Intravenous nitroglycerine
O
Outcome
Haemodynamic effects and symptomatic improvement
Nesiritide provides rapid haemodynamic and symptomatic improvement in acutely decompensated heart failure and is superior to intravenous nitroglycerine.
Cite This Study
Hobbs et al. (2001) studied this question.